229000 — Gencurix Share Price
- KR₩28bn
- KR₩33bn
- KR₩5bn
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.93 | ||
Price to Tang. Book | 2.04 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 5.61 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -16.44% | ||
Return on Equity | -25.31% | ||
Operating Margin | -52.57% |
Financial Summary
Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | KR₩m | 1,571.99 | 3,046.95 | 2,559.49 | 2,600.32 | 5,133.77 | n/a | n/a | 106.53% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Gencurix Inc. is a Korea-based company mainly engaged in the sale of medical equipments. In addition, the Company is involved in the manufacturing and sale of breast cancer test (BCT) kits, Korean genetic polymorphism diagnostic kits, lung cancer and colorectal cancer diagnostic kits. The BCT kits are used for analyzing the expression level of the cancer-related gene. The products are sold under the name of GenesWell.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 21st, 2011
- Public Since
- October 27th, 2015
- No. of Shareholders
- 9,579
- No. of Employees
- 68
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Korea Exchange - KOSDAQ
- Shares in Issue
- 15,801,971

- Address
- 402-404, SEOUL, 08382
- Web
- http://www.gencurix.com/
- Phone
- +82 226217038
- Auditors
- Tae Sung Accounting
Upcoming Events for 229000
Q2 2025 Gencurix Inc Earnings Release
Similar to 229000
Access Bio
Korea Exchange - KOSDAQ
Aligned Genetics
Korea Exchange - KOSDAQ
Alphanox Co
Korea Exchange - KOSDAQ
Angel Robotics Co
Korea Exchange - KOSDAQ
Asta Co
Korea Exchange - KOSDAQ
FAQ
As of Today at 20:46 UTC, shares in Gencurix are trading at KR₩1,824. This share price information is delayed by 15 minutes.
Shares in Gencurix last closed at KR₩1,824 and the price had moved by -39.57% over the past 365 days. In terms of relative price strength the Gencurix share price has underperformed the FTSE Developed Asia Pacific Index by -38.88% over the past year.
There is no consensus recommendation for this security.
Find out moreGencurix does not currently pay a dividend.
Gencurix does not currently pay a dividend.
Gencurix does not currently pay a dividend.
To buy shares in Gencurix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩1,824, shares in Gencurix had a market capitalisation of KR₩28bn.
Here are the trading details for Gencurix:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 229000
Based on an overall assessment of its quality, value and momentum Gencurix is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Gencurix. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -11.38%.
As of the last closing price of KR₩1,824, shares in Gencurix were trading -16.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Gencurix PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩1,824.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Gencurix's directors